ES2196349T3 - Uso de galanina para reparar lesiones en los nervios. - Google Patents

Uso de galanina para reparar lesiones en los nervios.

Info

Publication number
ES2196349T3
ES2196349T3 ES97932939T ES97932939T ES2196349T3 ES 2196349 T3 ES2196349 T3 ES 2196349T3 ES 97932939 T ES97932939 T ES 97932939T ES 97932939 T ES97932939 T ES 97932939T ES 2196349 T3 ES2196349 T3 ES 2196349T3
Authority
ES
Spain
Prior art keywords
galanin
treatment
galanine
nerves
supression
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES97932939T
Other languages
English (en)
Inventor
David Wynick
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Neurotargets Ltd
Original Assignee
Neurotargets Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9615551.0A external-priority patent/GB9615551D0/en
Priority claimed from GBGB9623869.6A external-priority patent/GB9623869D0/en
Application filed by Neurotargets Ltd filed Critical Neurotargets Ltd
Application granted granted Critical
Publication of ES2196349T3 publication Critical patent/ES2196349T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0276—Knock-out vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/0306—Animal model for genetic diseases
    • A01K2267/0312—Animal model for Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/0306—Animal model for genetic diseases
    • A01K2267/0318—Animal model for neurodegenerative disease, e.g. non- Alzheimer's
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/035—Animal model for multifactorial diseases
    • A01K2267/0356—Animal model for processes and diseases of the central nervous system, e.g. stress, learning, schizophrenia, pain, epilepsy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Biotechnology (AREA)
  • Endocrinology (AREA)
  • Wood Science & Technology (AREA)
  • Environmental Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Animal Husbandry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biodiversity & Conservation Biology (AREA)

Abstract

ESTA INVENCION SE RELACIONA CON LA GALANINA Y SU UTILIZACION. CONCRETAMENTE, LA INVENCION PROPORCIONA UN RATON MUTANTE QUE CARECE DE UN GEN FUNCIONAL DE LA GALANINA. EL RATON SE PUEDE UTILIZAR PARA INVESTIGAR LOS EFECTOS DE LA GALANINA. TAMBIEN SE HA DESCUBIERTO INESPERADAMENTE QUE LOS ANTAGONISTAS DE LA GALANINA SE PUEDEN UTILIZAR PARA TRATAR EL DOLOR, CONCRETAMENTE, NEUROPATIAS DOLOROSAS, LA ELIMINACION DEL DOLOR, EN LA SUPRESION DE LA LACTACION, EN EL TRATAMIENTO DEL PROLACTINOMA Y EN ANESTESIA. ADEMAS, EL USO DE LOS AGONISTAS DE LA GALANINA SE PUEDE APLICAR AL TRATAMIENTO DEL ALZHEIMER, EN LA MEJORA DE LA MEMORIA Y DEL CONOCIMIENTO Y EN EL TRATAMIENTO DE LAS LESIONES NERVIOSAS, ASI COMO EN LA PROMOCION DE LA REGENERACION DE LOS NERVIOS.
ES97932939T 1996-07-24 1997-07-24 Uso de galanina para reparar lesiones en los nervios. Expired - Lifetime ES2196349T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9615551.0A GB9615551D0 (en) 1996-07-24 1996-07-24 Galanin
GBGB9623869.6A GB9623869D0 (en) 1996-11-15 1996-11-15 Galanin

Publications (1)

Publication Number Publication Date
ES2196349T3 true ES2196349T3 (es) 2003-12-16

Family

ID=26309752

Family Applications (2)

Application Number Title Priority Date Filing Date
ES02028584T Expired - Lifetime ES2340984T3 (es) 1996-07-24 1997-07-24 Utilizacion de un agonista de galanina en la preparacion de un medicamento para mejorar la memoria y otras funciones cognitivas.
ES97932939T Expired - Lifetime ES2196349T3 (es) 1996-07-24 1997-07-24 Uso de galanina para reparar lesiones en los nervios.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ES02028584T Expired - Lifetime ES2340984T3 (es) 1996-07-24 1997-07-24 Utilizacion de un agonista de galanina en la preparacion de un medicamento para mejorar la memoria y otras funciones cognitivas.

Country Status (11)

Country Link
US (1) US20030009777A1 (es)
EP (2) EP1342410B1 (es)
JP (1) JP2000516212A (es)
AT (2) ATE237346T1 (es)
AU (1) AU3630297A (es)
DE (2) DE69721005T2 (es)
DK (2) DK0918455T3 (es)
ES (2) ES2340984T3 (es)
GB (1) GB2331301C (es)
PT (2) PT1342410E (es)
WO (1) WO1998003059A1 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2216227A1 (en) 1996-01-24 1997-07-31 Synaptic Pharmaceutical Corporation Dna encoding galanin galr2 receptors and uses thereof
US6329197B2 (en) 1996-10-09 2001-12-11 Synaptic Pharmaceutical Corporation DNA encoding galanin GALR3 receptors and uses thereof
JP2005507654A (ja) * 2001-08-27 2005-03-24 トゥラリック インコーポレイテッド 増幅した癌遺伝子およびそれらの癌への関与
AU2003211562A1 (en) * 2002-02-22 2003-09-09 Takeda Chemical Industries, Ltd. Novel dna and use thereof
GB0403509D0 (en) * 2004-02-17 2004-03-24 Neuro Targets Ltd Galanin receptors and brain injury
AU2005299771A1 (en) * 2004-10-21 2006-05-04 High Point Pharmaceuticals, Llc Bissulfonamide compounds as agonists of GalR1, compositions, and methods of use
GB0523550D0 (en) 2005-11-18 2005-12-28 Hunter Fleming Ltd Therapeutic uses of steroidal compounds
AU2008207287A1 (en) * 2007-01-19 2008-07-24 Howard Florey Institute Of Experimental Physiology And Medicine Use of galanin in a method of treating neurodegenerative diseases or conditions
WO2009040034A2 (en) * 2007-09-11 2009-04-02 Mondobiotech Laboratories Ag Use of a peptide as a therapeutic agent
CA2699220A1 (en) * 2008-09-09 2010-03-18 Mondobiotech Laboratories Ag Use of a peptide as a therapeutic agent
ES2883838A1 (es) * 2020-06-04 2021-12-09 Univ Malaga Prevencion y/o tratamiento del deterioro cognitivo asociado a sindromes de demencia

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU1350792A (en) * 1991-01-16 1992-08-27 General Hospital Corporation, The Human galanin
AU1462692A (en) * 1991-02-25 1992-09-15 Board Of Regents Of The University Of Washington, The Methods for detecting galanin antagonists
CA2105572A1 (en) * 1991-03-06 1992-09-07 Helen F. Evans Human galanin, cdna clones encoding human galanin and a method of producing human galanin
SE9101472D0 (sv) * 1991-05-15 1991-05-15 Trion Forskning & Utveckling Galanin antagonist
JPH06172387A (ja) * 1992-12-11 1994-06-21 Aibaitsu Kk 合成ペプチド誘導体
US6225282B1 (en) * 1996-01-05 2001-05-01 Genentech, Inc. Treatment of hearing impairments
CA2216227A1 (en) * 1996-01-24 1997-07-31 Synaptic Pharmaceutical Corporation Dna encoding galanin galr2 receptors and uses thereof

Also Published As

Publication number Publication date
ATE457125T1 (de) 2010-02-15
EP1342410A3 (en) 2003-12-10
EP0918455B1 (en) 2003-04-16
EP0918455A1 (en) 1999-06-02
EP1342410A2 (en) 2003-09-10
DK1342410T3 (da) 2010-05-31
GB2331301A (en) 1999-05-19
GB9901264D0 (en) 1999-03-10
US20030009777A1 (en) 2003-01-09
ES2340984T3 (es) 2010-06-14
DE69721005D1 (de) 2003-05-22
JP2000516212A (ja) 2000-12-05
DE69721005T2 (de) 2004-06-09
PT1342410E (pt) 2010-05-11
WO1998003059A1 (en) 1998-01-29
PT918455E (pt) 2003-09-30
ATE237346T1 (de) 2003-05-15
DE69739760D1 (de) 2010-03-25
AU3630297A (en) 1998-02-10
EP1342410B1 (en) 2010-02-10
GB2331301C (en) 2005-05-22
DK0918455T3 (da) 2003-08-04
GB2331301B (en) 2001-02-14

Similar Documents

Publication Publication Date Title
IL267381A (en) A pharmaceutical preparation containing dextromethorphan and quinidine for the treatment of nervous disorders
SE9803710D0 (sv) Use of certain drugs for treating nerve root injury
DK1135153T3 (da) Anvendelser af EPH-receptorantagonister og -agonister til behandling af vaskulære forstyrrelser
EP1428821A8 (en) Piperidin-4-yl amines with analgesic effect
ATE490786T1 (de) Behandlung von verletzungen des zentralen nervensystems
BR0314053A (pt) Pirazolopiridinas e métodos de obtenção e uso das mesmas
ES2196349T3 (es) Uso de galanina para reparar lesiones en los nervios.
EA200200132A1 (ru) СЕЛЕКТИВНЫЕ АНТАГОНИСТЫ РЕЦЕПТОРА iGluRДЛЯ ЛЕЧЕНИЯ МИГРЕНИ
BR9811780A (pt) Método de aumento de volume ósseo usando agonistas seletivos fp não ocorrendo naturalmente
BG105256A (en) Muscarinic agonists and antagonists
SE9802208D0 (sv) Novel compounds
BR9711225A (pt) Composi-{es de propentofilina transd-rmica para o tratamento do mal de alzheimer
DE60233350D1 (de) IMIDAZOi2,1-B -1,3,4-THIADIAZOLE SULFONAMIDES
BR0012327A (pt) Pirrolidinas e piperidinas neurotróficas, e composições e métodos relacionados
HK1041633A1 (en) Composition and use of rar antagonists for promoting chondrogenesis
BR9713538A (es)
BR0015424A (pt) Análogos de ácido hidroxieicosatetraenóico e, métodos de seu uso em tratamento de distúrbios de olho seco
EA200200656A1 (ru) НОВЫЕ ТЕРАПЕВТИЧЕСКИЕ КОМБИНАЦИИ (S)-2-(БЕНЗИЛАМИНОМЕТИЛ)-2,3,8,9-ТЕТРАГИДРО-7H-1,4-ДИОКСИН [2,3-е]ИНДОЛ-8-ОНА И НЕЙРОЛЕПТИКОВ ДЛЯ ЛЕЧЕНИЯ ИЛИ ПРЕДОТВРАЩЕНИЯ ПСИХОТИЧЕСКИХ РАССТРОЙСТВ
EE200100122A (et) R-(+)-alfa-(2,3-dimetoksüfenüül)-1-[2-(4-fluorofenüül)etüül]-4-piperidiinmetanooli kasutamine unehäirete raviks
SE9803276D0 (sv) Use of certain drugs for treating nerve root injury